Literature DB >> 7594720

Cross-neutralization of hantaviruses with immune sera from experimentally infected animals and from hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome patients.

Y K Chu1, G Jennings, A Schmaljohn, F Elgh, B Hjelle, H W Lee, S Jenison, T Ksiazek, C J Peters, P Rollin.   

Abstract

Plaque-reduction neutralization tests were done with eight of nine known representative hantaviruses and immune sera from experimentally infected animals and from patients with hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). Results obtained with animal sera demonstrated each virus to be antigenically unique. Neutralization with the HPS patient sera was highest with Sin Nombre (SN) virus and to a lesser extent with Black Creek Canal (BCC) virus. Sera from Korean HFRS patients reacted best with Hantaan virus, but cross-reactivity with all other viruses except Thottapalayam (TPM) virus was also observed. Sera from Swedish HFRS patients reacted best with Puumala virus but cross-reacted with Prospect Hill, SN, and BCC viruses and to a lesser extent with all of the other viruses except TPM virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594720     DOI: 10.1093/infdis/172.6.1581

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Phylogenetic and geographical relationships of hantavirus strains in eastern and western Paraguay.

Authors:  Yong Kyu Chu; Brook Milligan; Robert D Owen; Douglas G Goodin; Colleen B Jonsson
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

Review 2.  A global perspective on hantavirus ecology, epidemiology, and disease.

Authors:  Colleen B Jonsson; Luiz Tadeu Moraes Figueiredo; Olli Vapalahti
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

3.  Development of serological assays for Thottapalayam virus, an insectivore-borne Hantavirus.

Authors:  Megumi Okumura; Kumiko Yoshimatsu; Sanit Kumperasart; Ichiro Nakamura; Michiko Ogino; Midori Taruishi; Araya Sungdee; Sirima Pattamadilok; Ima Nurisa Ibrahim; Sri Erlina; Takashi Agui; Richard Yanagihara; Jiro Arikawa
Journal:  Clin Vaccine Immunol       Date:  2006-12-20

4.  Nucleotide sequencing and serologic analysis of Cache Valley virus isolates from the Yucatan Peninsula of Mexico.

Authors:  Bradley J Blitvich; Maria A Loroño-Pino; Julian E Garcia-Rejon; Jose A Farfan-Ale; Karin S Dorman
Journal:  Virus Genes       Date:  2012-03-31       Impact factor: 2.332

5.  DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys.

Authors:  J W Hooper; D M Custer; E Thompson; C S Schmaljohn
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 6.  Human pathogenic hantaviruses and prevention of infection.

Authors:  Detlev H Krüger; Günther Schönrich; Boris Klempa
Journal:  Hum Vaccin       Date:  2011-06-01

7.  A midcourse assessment of hantavirus pulmonary syndrome.

Authors:  R E Shope
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

8.  New York 1 and Sin Nombre viruses are serotypically distinct viruses associated with hantavirus pulmonary syndrome.

Authors:  I Gavrilovskaya; R LaMonica; M E Fay; B Hjelle; C Schmaljohn; R Shaw; E R Mackow
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

9.  Monitoring Neutralization Property Change of Evolving Hantaan and Seoul Viruses with a Novel Pseudovirus-Based Assay.

Authors:  Tingting Ning; Ling Wang; Shuo Liu; Jian Ma; Jianhui Nie; Weijin Huang; Xuguang Li; Yuhua Li; Youchun Wang
Journal:  Virol Sin       Date:  2020-06-12       Impact factor: 4.327

10.  Novel hantavirus sequences in Shrew, Guinea.

Authors:  Boris Klempa; Elisabeth Fichet-Calvet; Emilie Lecompte; Brita Auste; Vladimir Aniskin; Helga Meisel; Patrick Barrière; Lamine Koivogui; Jan ter Meulen; Detlev H Krüger
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.